Asia 1Q Preview: Japan Policy Worries, Indian Mixed Bag
As major companies start to release their quarterly results over the next few weeks, Scrip and sister publication PharmAsia News take a market-by-market look at some of the key expectations, challenges and policy factors likely to have the biggest influence on Asia's major corporate players.
You may also be interested in...
The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.
A regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence on the Asian marketplace.
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.